This finding is due to the treatment groups’ higher increase in the share of patients with yearly examination of nephropathy status or intake of ACE inhibitors [DiD 2017/18: + 5.4 percentage points (95% CI 0.9; 10); DiD 2018/19: + 7.8 percentage-points (95% CI 3.3; 12)] and with ophthalmologic care every 2 years [DiD 2017/18: + 3.3 percentage-points (95% CI – 0.8; 7.5), statistically not significant; DiD 2018/19: + 6.3 percentage-points (95% CI 1.4; 11)]. This evidence concerns the gene ACE and kidney disorder.